NO20063106L - MRI-kontrastmediumsammensetning for oral administrasjon - Google Patents

MRI-kontrastmediumsammensetning for oral administrasjon

Info

Publication number
NO20063106L
NO20063106L NO20063106A NO20063106A NO20063106L NO 20063106 L NO20063106 L NO 20063106L NO 20063106 A NO20063106 A NO 20063106A NO 20063106 A NO20063106 A NO 20063106A NO 20063106 L NO20063106 L NO 20063106L
Authority
NO
Norway
Prior art keywords
mri contrast
oral administration
contrast medium
medium composition
promoter
Prior art date
Application number
NO20063106A
Other languages
English (en)
Norwegian (no)
Inventor
Nils-Olof Johansson
Original Assignee
Cmc Contrast Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cmc Contrast Ab filed Critical Cmc Contrast Ab
Publication of NO20063106L publication Critical patent/NO20063106L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/103—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being acyclic, e.g. DTPA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/32—Manganese; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
NO20063106A 2003-12-19 2006-07-04 MRI-kontrastmediumsammensetning for oral administrasjon NO20063106L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0303429A SE527491C2 (sv) 2003-12-19 2003-12-19 Kontraktsmedelskomposition för magnetisk resonanstomografi för oral administration
PCT/SE2004/001644 WO2005058375A1 (en) 2003-12-19 2004-11-10 Mri contrast medium composition for oral administration

Publications (1)

Publication Number Publication Date
NO20063106L true NO20063106L (no) 2006-09-18

Family

ID=30768766

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20063106A NO20063106L (no) 2003-12-19 2006-07-04 MRI-kontrastmediumsammensetning for oral administrasjon

Country Status (15)

Country Link
US (1) US20070065520A1 (de)
EP (2) EP1694367A1 (de)
JP (1) JP4731493B2 (de)
KR (1) KR101131362B1 (de)
AT (1) ATE499117T1 (de)
AU (1) AU2004298396B2 (de)
CA (1) CA2549890C (de)
DE (1) DE602004031569D1 (de)
DK (1) DK2060273T3 (de)
ES (1) ES2363917T3 (de)
NO (1) NO20063106L (de)
RU (1) RU2361618C2 (de)
SE (1) SE527491C2 (de)
TW (1) TWI334787B (de)
WO (1) WO2005058375A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011003818A2 (en) 2009-07-06 2011-01-13 Cmc Contrast Ab Diagnostic method
ES2764408T3 (es) 2013-08-28 2020-06-03 Promethera Biosciences S A / N V Procedimiento para la producción de células progenitoras hepáticas adultas
KR102101060B1 (ko) * 2014-08-28 2020-04-16 프로메테라 바이오사이언시즈 에스.에이./엔.브이. 성체 간 전구 세포의 제조 방법
RU2577298C1 (ru) * 2014-10-01 2016-03-10 Общество с ограниченной ответственностью "МедКонтрастСинтез" (ООО "МедКонтрастСинтез") Гепатотропное магнитно-резонансное средство
KR101864992B1 (ko) * 2017-03-09 2018-07-04 국립암센터 Mri 노이즈 제거용 조성물 및 이를 이용한 패드
KR102381029B1 (ko) * 2019-04-05 2022-03-31 연세대학교 산학협력단 대사체를 유효성분으로 포함하는 신규한 조영제 조성물
CA3140098A1 (en) 2019-06-07 2020-12-10 Ascelia Pharma AB Compressed solid composition for mri

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4863898A (en) * 1986-02-06 1989-09-05 Albion International, Inc. Amino acid chelated compositions for delivery to specific biological tissue sites
NO884225L (no) 1987-09-25 1989-03-28 Salutar Inc Nmr-bildedannelse mn(ii)- koordinasjonsforbindelser.
GB8801646D0 (en) * 1988-01-26 1988-02-24 Nycomed As Chemical compounds
WO1996005867A2 (en) * 1994-08-18 1996-02-29 Nycomed Imaging A/S Compositions
DK81095A (da) * 1995-07-11 1997-01-12 Henrik S Thomsen Peroralt MR-kontraststof til lever og øvre tarmkanal
WO1998011922A2 (en) * 1996-02-16 1998-03-26 Nycomed Imaging As Method
GB9619758D0 (en) * 1996-09-23 1996-11-06 Nycomed Imaging As Method

Also Published As

Publication number Publication date
AU2004298396A1 (en) 2005-06-30
DK2060273T3 (da) 2011-05-23
EP2060273A2 (de) 2009-05-20
RU2361618C2 (ru) 2009-07-20
DE602004031569D1 (de) 2011-04-07
SE0303429D0 (sv) 2003-12-19
KR20070027501A (ko) 2007-03-09
SE527491C2 (sv) 2006-03-21
TWI334787B (en) 2010-12-21
AU2004298396B2 (en) 2010-06-17
EP2060273A3 (de) 2009-09-30
ES2363917T3 (es) 2011-08-19
ATE499117T1 (de) 2011-03-15
WO2005058375A1 (en) 2005-06-30
KR101131362B1 (ko) 2012-04-04
EP1694367A1 (de) 2006-08-30
CA2549890A1 (en) 2005-06-30
TW200520777A (en) 2005-07-01
US20070065520A1 (en) 2007-03-22
EP2060273B1 (de) 2011-02-23
CA2549890C (en) 2012-09-18
RU2006126072A (ru) 2008-01-27
SE0303429L (sv) 2005-06-20
JP4731493B2 (ja) 2011-07-27
JP2007514740A (ja) 2007-06-07

Similar Documents

Publication Publication Date Title
US5456602A (en) Dental bonding
Witzel et al. Prophylactic endoscopic sclerotherapy of oesophageal varices: a prospective controlled study
Kevorkian et al. Leiomyosarcoma of large arteries and veins
Pye et al. Study of serum C-reactive protein concentration in cardiac failure.
Yang et al. Atherosclerotic plaque-targeted nanotherapeutics ameliorates atherogenesis by blocking macrophage-driven inflammation
Yap et al. Short-term fluoride release from various aesthetic restorative materials
NO20063106L (no) MRI-kontrastmediumsammensetning for oral administrasjon
Kalambokis et al. The effects of chronic treatment with octreotide versus octreotide plus midodrine on systemic hemodynamics and renal hemodynamics and function in nonazotemic cirrhotic patients with ascites
Kang et al. Hypotensive effect of butein via the inhibition of angiotensin converting enzyme
DK220484A (da) Enteralt kontrastmiddel til kernespintomografi og dets fremstilling
DOP2006000154A (es) Composiciones que contienen partículas magnéticas de óxido de hierro, y uso de dichas composiciones en métodos de diagnóstico por imágenes
Zivkovi et al. Bacterial penetration of restored cavities
Gönülol et al. Effect of thermal aging on microleakage of current flowable composite resins
Zhu et al. Isolation, identification, molecular docking analysis, and cytoprotection of seven novel angiotensin I-converting enzyme inhibitory peptides from miiuy croaker byproducts-swim bladders
Borges et al. Multi-acrylamides improve bond stability through collagen reinforcement under physiological conditions
JPH048368A (ja) プライマー組成物
WO2002100885A3 (en) A penta- or tetrapeptide binding to somatostatin receptors and the use of the same
Bustamante et al. Specificity of neutral amino acid uptake at the basolateral side of the epithelium in the cat salivary gland in situ.
Brown et al. Low grade gastric MALT Lymphoma: radiographic findings
Nagasue et al. Serum alpha‐fetoprotein levels after hepatic artery ligation and postoperative chemotherapy. Correlation with clinical status in patients with hepatocellular carcinoma
BRPI0416461A (pt) método para o tratamento de episódios de sangramento, formulação farmacêutica, e, uso de um polipeptìdeo fxi
Wirthlin JR Acid-reacting stains, softening, and bacterial invasion in human carious dentin
Song et al. Downregulatory effect of extracts from mistletoe (Viscum album) and pueraria root (Pueraria radix) on cellular NF-κB activation and heir antioxidant activity
Sharma Selected pulmonary cutaneous syndromes
Hayes et al. Submucous lipoma of the colon: Review of the literature and report of four cases

Legal Events

Date Code Title Description
CREP Change of representative

Representative=s name: BRYN AARFLOT AS, POSTBOKS 449 SENTRUM, 0104 OSLO,

FC2A Withdrawal, rejection or dismissal of laid open patent application